Zydus Cadila is listed on the stock exchange as Cadila Healthcare.
In order to achieve this target, the company has entered into new segments like biosimilars. Foray into this new segment has helped the company to receive the marketing authorisation of biosimilar version of Erythropoietin (EPO) in the Indian market in FY 2011. EPO is very useful in the treatment of anaemia and in special cases where the blood count of the patient goes down.
According to a company statement, "The Company has completed clinical trials of biosimilar versions of Teriparatide, which is meant for treatment of osteoporosis, and PEG-IFNa-2b, used for treating chronic hepatitis infections."
In addition to this, Zydus has also got the permission and approval from US-FDA for conduction clinical trials of ZYGK1 (glucokinase activator) to lower blood glucose and IND-ZYD1 which is used for the treatment of diabetes.